跳至主要内容
临床试验/jRCT2031240583
jRCT2031240583进行中(未招募)不适用

A study of pharmacokinetics and safety on repeated application of flurbiprofen-containing patch (Tape) (LC1702) in healthy adult males.

LEAD CHEMICAL Co.,Ltd.0 个研究点目标入组 8 人开始时间: 2025年1月10日最近更新:

试验速览

阶段
不适用
状态
进行中(未招募)
入组人数
8
主要终点
-

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Randomized Controlled Trial
干预模型
Crossover Assignment
主要目的
Treatment Purpose
盲法
Open(masking Not Used)

入排标准

年龄范围
18age old over 至 40age old under(—)
性别
Male

入选标准

  • (1) Age: 18 to 40 years old (at the time of obtaining consent)
  • (2) Persons whose BMI [Body Mass Index: weight (kg) / height (mm)^2] is 18.5 kg/m^2 or more and less than 25 kg/m^2 (numbers are not rounded)
  • (3) Persons who can quit smoking during their stay

排除标准

  • (1) Persons with hypersensitivity or idiosyncrasy to drugs, etc.
  • (2) Persons with a history of bronchial asthma.
  • (3) Persons with diseases of the gastrointestinal tract, heart, liver, kidneys, etc. that affect drug metabolism and excretion.
  • (4) Persons with skin wounds at the application site, and those who have skin symptoms such as eczema, contact dermatitis, psoriasis, seborrheic dermatitis, dyschromatosis, and excessive sunburn at the application site.

结局指标

主要结局

-

Drug concentration in plasma

次要结局

未报告次要终点

研究者

相似试验